Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†

M. De Santis1,2*, P. J. Wiechno3, J. Bellmunt4, C. Lucas5, W.-C. Su6, L. Albiges7, C.-C. Lin8, E. Senkus-Konefka9, A. Flechon10, L. Mourey11, A. Necchi12, W. C. Loidl13, M. M. Retz14, N. Vaissière5 & S. Culine15

1Ludwig Boltzmann Institute for ACR VIEIena/LB-CTO ACR-ITR VIEIena, KFJ-Spital, Vienna, Austria; 2Cancer Research Centre, University of Warwick, Coventry, UK; 3Oncology Institute, Institut im Sklodowsklej-Curie, Warsaw, Poland; 4Dana-Farber Cancer Institute-Harvard Medical School, Boston, USA; 5Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France; 6Department of Internal Medicine, National Cheng Kung University Hospital, Taipei, Taiwan; 7Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; 8Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; 9Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; 10Department of Medicine, Centre Léon Bérard, Lyon; 11Department of Oncology, Institut Claudius Regaud, Toulouse, France; 12Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 13Department of Urology, KH Barmherzige Schwestern Linz, Linz, Austria; 14Department of Urology, University Hospital Rechts Der Isar, Munich, Germany; 15Department of Medical Oncology, Hopital Saint-Louis–APHP, Paris-Diderot University, Paris, France

Received 10 August 2015; revised 2 December 2015; accepted 5 December 2015

Background: There is no standard first-line chemotherapy for advanced urothelial carcinoma (aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the efficacy and tolerability profile of two vinflunine-based cytotoxic regimens in this setting.

Patients and methods: Patients with aUC a creatinine clearance (CrCl) of 260 but ≥30 ml/min, performance status 0 or 1 and no prior chemotherapy for advanced disease were randomized (1:1). They received vinflunine 250 or 280 mg/m2 (based on baseline CrCl) on day 1, plus either gemcitabine [750 mg/m2 escalated to 1000 mg/m2 in cycle 2 if no toxicity grade (G) ≥2 on days 1 and 8 (VG) or plus carboplatin area under the curve 4.5 day 1 (VC) every 21 days). To detect a 22% improvement in each arm compared with H0 (41%) in the primary end point, disease control rate (DCR = complete response + partial response + stable disease), 31 assessable patients per arm were required (α = 5%, β = 20%).

Results: Sixty-nine patients were enrolled (34 VG, 35 VC). Less G3/4 haematological AEs were reported with VG: neutropaenia was seen in 38% (versus 68% with VC) and febrile neutropaenia in 3% (versus 14% with VC) of patients. No major differences were observed for non-haematological AEs. DCR was 77% in both groups; overall response rate (ORR) was 44.1% versus 28.6%, with a median progression-free survival of 5.9 versus 6.1 months and median OS of 14.0 versus 12.8 months with VG and VC, respectively.

Conclusion: Both vinflunine-based doublets offer a similar DCR, ORR and OS. The better haematological tolerance favours the VG combination, which warrants further study.

ClinicalTrials.gov protocol identifier: NCT 01599013.

Key words: vinflunine, urothelial carcinoma, bladder cancer, cisplatin-ineligible, renal impairment

introduction

Urothelial carcinoma (UC) counts for 429 793 new cases per year with 165 068 related deaths worldwide [1]. The standard of care for advanced and metastatic disease is cisplatin-based chemotherapy [2]. The response rate with these regimens is ~50% and median overall survival (OS) 13–15 months [3]. Up to 50% of the patients with advanced or metastatic UC are not eligible for cisplatin, generally due to impaired renal function and/or a performance status (PS) of ≥2, but also comorbidities such as congestive heart failure, peripheral neuropathy or hearing loss should be taken into account [3, 4]. So far, no standard treatment for such patients has been defined and there are currently only few ongoing trials, in particular phase II trials.
with immunotherapy that also include this patient population. Generally, carboplatin-based combinations or single agents are used in such patients. However, the benefit with carboplatin-based chemotherapy is modest, and OS usually does not exceed 8–9 months [2, 3, 5, 6]. Vinflunine, as a single agent, was approved by the EMA in 2009 for patients with advanced or metastatic UC after the failure of a platinum-based regimen [7, 8]. In addition, vinflunine has shown to be safe also in patients with significant renal impairment [7, 9].

Based on these data, a potential benefit of first-line vinflunine combinations in cisplatin-unfit patients with advanced or metastatic UC was hypothesized. Phase I trials assessed vinflunine combinations in cisplatin-unfit patients [10, 11]. This randomized phase II study was aimed at exploring the feasibility as well as clinical efficacy and tolerability profiles of two vinflunine combinations in UC patients.

**patients and methods**
This was a randomized two-arm, open-label, multinational phase II trial.

**patients**
Eligible patients had histologically confirmed locally advanced or metastatic UC (transitional cell predominant, urinary bladder or upper tract) with measurable disease as defined by RECIST (version 1.1), age between 18 and 79 years and ECOG PS 0 or 1. No prior systemic chemotherapy was allowed except for perioperative chemotherapy if relapse occurred ≥6 months after the last dose. All patients had to be ineligible for a cisplatin-based therapy based on renal function impairment [calculated creatinine clearance (CrCl)] by the Cockcroft–Gault formula of <60 ml/min but ≥30 ml/min] and/or congestive heart failure (NYHA Classification stages II–III). Adequate bone marrow function (absolute neutrophils ≥2000/mm³, haemoglobin ≥10 g/dl, platelets ≥100 000/mm³), normal hepatic function, absence of known brain metastases, leptomeningeal involvement and peripheral neuropathy Grade ≥2 by NCI Common Toxicity Criteria (CTC) were required.

The most important exclusion criteria were any serious medical condition including infection or unstable cardiac disease, ongoing immune therapy, treatment with any potent cytochrome 3A4 inhibitor or inducer, the presence of other malignancies with a disease-free interval of <5 years with the exception of cured skin basal carcinoma, in situ cervix carcinoma and incidentally discovered localized prostate cancer (pT ≤T2b, Gleason score ≤7).

The protocol was approved by the national and institutional ethics review boards of each participating institution, whatever applicable. Before randomization, written informed consent was obtained from all patients in accordance with the Declaration of Helsinki, applicable guidelines for good clinical practice and regulations of the participating countries.

**treatment plan**
Patients were centrally randomized 1:1 and stratified (minimization procedure) for study site, prior perioperative chemotherapy (yes or no), PS0 versus PS1 and pre-treatment CrCl (≥60 versus 40–60 versus 30–40 ml/min) and subsequently randomly assigned 1:1 to receive either vinflunine–gemcitabine (VG) or vinflunine–carboplatin (VC).

On the basis of the CrCl at randomization (<40 or ≥40 ml/min), patients received every 21 days vinflunine 250 or 280 mg/m² as a 20 min i.v. infusion on day 1, plus either a 30 min i.v. infusion of gemcitabine 750 mg/m² days 1 and 8, escalated to 1000 mg/m² in cycle 2 if no toxicity grade of ≥2 occurred (VG) or carboplatin area under the curve 4.5 day 1 over 1 h i.v. (VC). Treatment was continued until disease progression, intolerable toxicity or patient refusal. In case of complete response, two more cycles were to be given after the response confirmation and further treatment prolongation was left at the physician’s discretion. Subsequent cycles were administered if ANC was >1500/mm³ (2000 at baseline), and/or platelets count >75 000/mm³ (100 000 at baseline); all study drugs were held if CrCl was below 20 ml/min.

Secondary granulocyte colony-stimulating factor was given in case of febrile neutropaenia, G4 asymptomatic neutropaenia lasting >7 days or a neutropenic infection. One dose reduction was allowed for vinflunine, down to either 250 or 225 mg/m² (depending on the starting dose) in case of neutropaenia G4 >7 days, febrile neutropaenia, mucositis or constipation G2 ≥5 days or G ≥3 of any duration, any other G ≥3 toxicity related to the study drug (including G3–4 thrombocytopenia with bleeding) except G3 inadequately treated or premedicated vomiting, nausea or fatigue. No dose re-escalation was allowed after a dose reduction.

**objectives and clinical assessment**
The primary objective of the study was to determine the disease control rate (DCR). This was defined by complete response (CR) + partial response (PR) + stable disease (SD) for both vinflunine-based combinations in the intent-to-treat (ITT) population (first assessment at week 6). Tumour assessment (RECIST1.1) and confirmation of response was carried out by the centre radiologist (chest, pelvic and abdominal and pelvic computed tomography scans or magnetic resonance imaging, bone scan and X-rays in case of bone lesions) at baseline and every 6 weeks. Patients who progressed before the first evaluation were classified as early progression and early death if dying before first treatment assessment.

Toxicity was evaluated according to NCI CTC (version 2.0) before each chemotherapy administration; pre-treatment electrocardiogram and audiogram were required.

Secondary efficacy endpoints included overall response rate (ORR), both best overall response and objective confirmed response), duration of disease control (DC), duration of SD, duration of response, time to first response, progression-free survival (PFS) and OS.

**statistical methods**
The null hypothesis H0 was based on the DCR observed with vinflunine single agent in the post-platinum setting. For H1, 38% ORR plus 25% SD rate was selected based on results observed with carboplatin and gemcitabine in unfit patients [12, 13]. With α 5% and β of 20%, 31 assessable patients per arm were needed to detect a DCR improvement of 22% within each arm compared with H0 (41%), the alternative hypothesis H1 being 63%. Assuming 10% non-assessable patients, a total of 68 patients were to be randomized. The primary efficacy analysis of the DCR was planned in the ITT population with 95% confidence interval (CI). Time-dependent parameters, OS, PFS, duration of response and DCR were analyzed with the Kaplan–Meier method. All treated patients were considered for the toxicity analyses. SAS® system software version 9.3 was used for the statistical analysis.

**results**
From February 2011 to August 2012, 69 patients were enrolled in 23 centres from 6 European countries and Taiwan; 34 in the VG arm and 35 in the VC arm (flow chart see supplementary Figure S1, available at *Annals of Oncology* online); all received at least one dose of the study drugs. The cut-off date for the final analysis was 10 April 2014. At that time, no more patients were on study treatment. The median follow-up was 25.9 months (95% CI 24.3–26.5) with 74% deaths in each arm.
patient characteristics
Baseline demographics were generally well balanced between the two treatment groups. There was a slight imbalance on the primary tumour location: upper urinary tract (UUT) 50% (VG) versus 43% (VC). Slightly more patients on VG had metastatic disease (88% on VG versus 77% on VC). All patients had a CrCl of <60 ml/min (median CrCl of 46 ml/min). Most patients had two or more comorbidities. Detailed patient characteristics are summarized in Table 1.

drug exposure
The median number of cycles was 5 (range 1–17) for VG and 4 (range 1–11) for VC. Three patients (9%) in each arm received only one cycle. None of these early interruptions was a consequence of a drug-related adverse event (AE). The planned gemcitabine dose escalation from 750 to 1000 mg/m² in cycle 2 for the VG group was possible in 16/31 patients (52%). The median relative dose intensity for vinflunine was 97.4% and 91.3%. Vinflunine dose-reduction was indicated in 6 (18%) and 7 (20%) patients, in the VG and VC arms, respectively. Main reasons for stopping treatment were progression in 23 patients (14 on VG and 9 on VC) and a drug-related AE in 20 patients (8 on VG and 12 on VC).

efficacy
The primary end point DCR was similar in both groups: 77% (Table 2). CR or PR were confirmed in 44% versus 29% of randomized patients (P = 0.215). Median PFS was of 5.9 versus 6.1 months and median OS was 14.0 versus 12.8 months (P = 0.860) on VG and VC, respectively.

At the time of analysis, 51 patients (25 on the VG and 26 on the VC arm) have died, 46 of which were due to disease progression. A 76-year-old woman died of a myocardial infarction in the setting of an underlying cardiovascular disease. Four additional patients died of non-drug-related reasons (worsening of general condition most probably secondary to unconfirmed disease progression in one case, death for unknown reasons that occurred several months after last study treatment in three patients).

safety
Myelosuppression was less pronounced with VG: G3–4 neutropenia occurred in 38% and 68% of patients (P = 0.028) and this was febrile in only one patient (3%) versus 5 (14%) on the VG and VC arms, respectively (Table 3). G3–4 thrombocytopenia was more pronounced on VC (with 21% versus 6% on VG). No associated bleeding was seen in either group.

Grade 3–4 non-haematological AEs (in >3% of patients) were reported in both arms, including asthenia/fatigue (22%), infection

Table 1. Patient demographics and clinical characteristics

| Main baseline characteristics (all patients randomized) | VG (N=34) | VC (N=35) |
|--------------------------------------------------------|-----------|-----------|
| Median age (years) [range]                              | 68 [46–79]| 72 [42–79]|
| ECOG PS 0/1, n (%)                                      | 15 (44%)/19 (56%) | 14 (40%)/21 (60%) |
| Primary tumour site, n (%)                              | 17 (50%) | 19 (54%) |
| Bladder                                                | 17 (50%) | 15 (43%) |
| U/per urinary tract                                     | 0        | 1 (3%) |
| Prior locoregional treatments, n (%)                   | 27 (79%)[50%] | 29 (83%)[37%] |
| Major surgery[a] involving kidney                      | 1 (3%)   | 4 (11%) |
| Radiotherapy                                            | 5 (15%)  | 6 (17%) |
| Prior neo- or adjuvant CT, n (%)                        | 4 (12%)  | 8 (23%) |
| Disease extent, n (%)                                   | 30 (88%) | 27 (77%) |
| Loco/regional                                          | 18 (53%) | 16 (46%) |
| Metastatic                                             | 10 (29%) | 8 (23%) |
| Comorbidities, n (%)                                   | 24 (7%)  | 8 (23%) |
| Cardiac disorders (at least 1)                         | 0 (0)/2 (6%) | 4 (11%)/2 (6%) |
| Congestive heart failure: stage I/ stage II             | 7 (21%)  | 7 (20%) |
| Diabetes                                               | 47.5 [30.8–59.8] | 45.0 [30.0–59.5] |
| Creatinine clearance: median [range] (ml/min), n (%)   | 40–<60 | 28 (82%) |
| ≥60 ml/min                                              | 6 (18%)  | 7 (20%) |

[a]Radical cystectomy, uretero-nephrectomy.

Table 2. Efficacy parameters and disease status

| VG (N=34) | VC (N=35) |
|-----------|-----------|
| Best ORR   | 52.9%     | 42.9%   |
| Confirmed ORR | 44.1%     | 28.6%   |
| Duration of confirmed ORR [median, months] | 8.2 | 7.7 |
| Tumour assessments, n (%)                      |           |         |
| Complete response                              | 3 (8%)    | 5 (14%) |
| Confirmed CR                                    | 2 (6%)    | 4 (11%) |
| Unconfirmed CR                                  | 1 (3%)    | 1 (3%)  |
| PR                                                | 15 (44%)  | 10 (29%) |
| Confirmed PR                                    | 13 (38%)  | 6 (17%) |
| Unconfirmed PR                                  | 2 (6%)    | 4 (11%) |
| Stable disease                                  | 8 (24%)   | 12 (34%) |
| Progression                                      | 6 (18%)   | 5 (14%) |
| Non-evaluable                                    | 2 (6%)    | 3 (9%)  |
| Disease control, n (%)                          | 26 (77%)  | 27 (77%) |
| 95% CI                                            | 58.8–89.3 | 59.9–89.6 |
| Duration of DC [median, months]                 | 7.2       | 8.3     |
| PFS [median, months] (censored 20)               | 5.9 [4.2–9.4] | 6.1 [4.6–10.4] |
| OS [median, months] (censored 23)                | 14.0 [8.3–20.1] | 12.8 [9.5–17.7] |
| Survival status, n (%)                          |           |         |
| Alive                                             | 7 (21%)   | 9 (26%) |
| Dead                                              | 25 (74%)  | 25 (71%)|
| Lost to follow-up                                 | 2 (6%)    | 0       |

ORR, objective response rate; CR, complete response; PR, partial response; DC, disease control; PFS, progression-free survival; OS, overall survival.
(7%) and constipation (4%) without major differences between arms (details in Table 3). Regarding events of special interest, no motor neuropathy was reported. One patient in each arm reported a G1 peripheral sensory neuropathy.

**discussion**

JASINT1 is the first study assessing the use of vinflunine combinations in this population of patients. The trial focuses on a homogeneous population of patients with good PS (0/1) and with impaired renal function as the single reason for being considered unfit for cisplatin.

Our trial population differs from that in two other published randomized studies in which patients with PS2 and/or renal impairment were enrolled [13, 14]. In these two studies, gemcitabine–carboplatin (GC) versus methotrexate, carboplatin, vincristine [13], and gemcitabine–oxaliplatin versus gemcitabine alone [14], were compared.

Other smaller sized uncontrolled trials also differ with respect to the definition for patients being unfit for cisplatin [6]. One trial with 25 patients who received sequential doxorubicin–gemcitabine followed by paclitaxel–carboplatin was conducted in favourably selected patients with PS ≤1 and inclusion criteria allowed for a solitary kidney as a reason for cisplatin ineligibility in addition to CrCl of <60 ml/min [15]. This is contrasted by our study in which distant metastases were present in 88% of patients and visceral disease in 49%. Such differences of inclusion criteria preclude any cross study efficacy comparison [16].

Another study by Balar et al. assessed the combination of bevacizumab with GC in 51 platinum-ineligible patients. This study included patients with a good Karnofsky index (92% of patients) but with renal dysfunction (76%). A solitary kidney or the presence of visceral metastases was also considered as the criterion for cisplatin ineligibility [17].

Indeed, in PS ≥2 patients, tolerance of chemotherapy is a relevant concern. It might differ substantially from that of good PS patients in whom efficacy usually is the driving end point. Interestingly, the only phase III trial in unfit patients, the EORTC trial 30986, that considered 2 criteria of cisplatin ineligibility (PS2 and/or GFR <60 ml/min) showed a high level of severe acute toxicities and a high degree of treatment abortion in patients presenting both criteria. These results prompted the authors to make a recommendation against the use of cytotoxic doublets in this particular patient group [13].

Comparing the baseline distribution of disease characteristics between the two treatment arms of our study, there was a slight imbalance concerning the primary tumour site and the presence of distant metastases favouring the VC arm. This imbalance limits the conclusions drawn for efficacy for the subgroups.

Our study population differs from others by a considerably higher rate of patients with UUT tumours (46%) [15, 17]. However, our trial, and despite an ‘unfit’ patient population, does not support the general assumption of a worse outcome of advanced or metastatic UUT tumours compared with those located in the urinary bladder. To date, no comparative prospective trial for metastatic UUT tumours versus bladder as the primary location has been published.

---

**Table 3. Adverse events (AE)**

| Possibly related AEs in ≥6% patients in at least one arm | VG (N = 34) | VC (N = 35) |
|--------------------------------------------------------|------------|------------|
|                                                        | All G | G3/4      | All G | G3/4      |
| N           | %    | N           | %    | N           | %    |
| Neutropaenia | 28   | 82         | 13   | 38         | 30   | 88         | 23   | 68         |
| Anaemia     | 33   | 97         | 9    | 27         | 34   | 100        | 9    | 27         |
| Thrombocytopaenia | 24   | 71         | 2    | 6          | 22   | 65         | 7    | 21         |
| Febrile neutropaenia | 1    | 3          | 1    | 3          | 5    | 14         | 5    | 14         |
| Bleeding or platelet transfusion with Thrombocytopaenia G3-4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asthenia—Fatigue | 20   | 58.8       | 8    | 23.5       | 15   | 42.9       | 7    | 20.0       |
| Infection   | 4    | 11.8       | 4    | 11.8       | 1    | 2.9        | 1    | 2.9        |
| Constipation | 10   | 29.4       | 1    | 2.9        | 14   | 40.0       | 2    | 5.7        |
| Ileus       | 0    | 0          | 0    | 0          | 1    | 2.9        | 1    | 2.9        |
| Flatulence  | 3    | 8.8        | 0    | 0          | 3    | 8.6        | 0    | 0          |
| Abdominal pain | 1    | 2.9        | 1    | 2.9        | 4    | 11.4       | 0    | 0          |
| Diarrhoea   | 2    | 5.9        | 0    | 0          | 3    | 8.6        | 0    | 0          |
| Dysphagia   | 3    | 8.8        | 0    | 0          | 0    | 0          | 0    | 0          |
| Stomatitis  | 7    | 20.6       | 1    | 2.9        | 7    | 20.0       | 1    | 2.9        |
| Nausea      | 12   | 35.3       | 0    | 0          | 16   | 45.7       | 0    | 0          |
| Vomiting    | 7    | 20.6       | 0    | 0          | 9    | 25.7       | 0    | 0          |
| Weight decrease | 9    | 26.5       | 1    | 2.9        | 8    | 22.9       | 0    | 0          |
| Decreased appetite | 10   | 29.4       | 0    | 0          | 11   | 31.4       | 0    | 0          |
| Musculoskeletal disorders, pain | 3    | 8.8 | 1    | 2.9        | 6    | 17.1       | 1    | 2.9        |
| Phlebitis (deep and superficial) | 4    | 11.8       | 0    | 0          | 1    | 2.9        | 0    | 0          |
| Pyrexia     | 5    | 14.7       | 0    | 0          | 2    | 5.7        | 0    | 0          |
| Alopecia    | 9    | 26.5       | 0    | 0          | 9    | 25.7       | 0    | 0          |

AE, adverse events.
We chose a cautious gemcitabine dose-escalation approach for the VG combination [18]. The results revealed that gemcitabine could be escalated in cycle 2 in only 52% of patients, which supports our conservative approach. Of note, using our per-protocol dosing schedules, both vinflunine combinations were feasible with a high percentage of adequate relative dose intensity for all drugs.

Haematological toxicity clearly favoured the VG combination. Compared with the most commonly used GC combination (EORTC 30986 study arm), less G3–4 neutropaenia (38.2% versus 52.5%), febrile neutropaenia (2.9% versus 4.2%) and in particular less G3–4 thrombocytopaenia (5.9% versus 48.3%) were observed with VG [13] and no toxic death was reported. In our study, the gastrointestinal tolerance of both VG and VC was better than previously reported with vinflunine single agent in the post-platinum setting [8, 19].

Regarding activity of the two regimens in our study, the statistical assumption was met for both combinations with a similar 77% DCR. The confirmed response rate favoured VG and all other efficacy parameters, including a PFS of 5.9 months, suggested high levels of activity that compares favourably with the best available chemotherapy data in this setting [6].

Although OS was not the primary end point in this study, the observed 14 months’ median OS in the VG group is promising in a cisplatin-unfit patient population with rather advanced and unfavourable disease characteristics. To put this into perspective, the most favourable subgroup out of the EORTC 30986 trial, 131 patients with PS0/1 and impaired renal function, showed a median OS of only 12 months [13].

There are clear limitations of our study. The absence of a non-investigational control arm precludes firm conclusions about any superiority of one of our treatment arms compared with other combination such as GC.

The primary end point of our study, DCR is not a standard end point for efficacy in this patient population. Therefore, the efficacy assumptions follow a general sense of clinically meaningful study end points in this disease but might be considered rather arbitrary. However, also other more commonly used end points for drug screening in small phase II single-arm UC trials like RECIST response have limited reliability [3, 20–24]. Duration of response or disease stabilization in the context of drug screening, as in our trial, might be more meaningful.

In conclusion, both vinflunine-based doublets were active while VG was better tolerated in cisplatin-unfit patients with a PS 0–1. The statistical assumption was met in both study groups with a DCR of 77%. The confirmed response rate of 44.1%, an OS of 14 months and less haematological toxicity favour the VG combination. These promising results warrant further development and are the basis for a planned comparison of VG with the widely used GC combination, for cisplatin-unfit patients.

acknowledgements

Julie Milot, Karine Legrand, Jean-Philippe Burillon and Maryse Morand contributed to this research.

funding

This study was supported by Pierre Fabre Research Institute, France. No grant number is applicable.

disclosure

NV and CL are employees of Pierre Fabre; MDS declared lecture and advisory board fees and a study grant from Pierre Fabre; JB declared lecture fees and an award from Pierre Fabre; ES-K declared honoraria for advisory role from Pierre Fabre; AF declared honoraria and clinical research sponsored by Pierre Fabre as well as transportation fees. LA declared advisory board fees from Novartis, Pfizer, Sanofi and Bayer and research funding from Novartis and Pfizer. All remaining authors have declared no conflicts of interest.

references

1. International Agency for Research on Cancer, World Health Organisation, GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr (18 August 2014, date last accessed).
2. Bellmunt J, Orsola A, Lewy JJ et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(suppl 3): iii40–iii48.
3. Witjes JA, Comperat E, Cowan NC et al. EAU guidelines on muscle-invasive and metastatic bladder cancer; summary of the 2013 guidelines. Eur Urol 2014; 65 (4): 778–792.
4. Galsky MD, Hahn NM, Rosenberg J et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011; 12(3): 211–214.
5. De Santos M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191–199.
6. Galsky MD, Hahn NM, Rosenberg J et al. Treatment of patients with metastatic urothelial cancer ‘unfit’ for cisplatin-based chemotherapy. J Clin Oncol 2011; 29 (17): 2432–2438.
7. Javor® European Public Assessment Report doc EMEA/CHMP/370293/2009.
8. Bellmunt J, Théodore C, Demirk T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urethral tract. J Clin Oncol 2009; 27: 4454–4461.
9. Isambert N, Delord JP, Tourani JF et al. How to manage intraurethral vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. Br J Clin Pharmacol 2014; 77(3); 498–508.
10. Tournoux-Facon C, Senellart H, Lemarie E et al. Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in chemotherapy patients. J Thorac Oncol 2011; 6(7): 1247–1253.
11. Tournoux-Facon C, Robinet G, Pinel MC et al. Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemotherapy patients with advanced non-small cell lung cancer. Am J Clin Oncol 2012; 35(4): 378–385.
12. Banias A, Mouloupolous LA, Koutas A et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A phase II study of the Hellenic Cooperative Oncology Group. Cancer 2006; 106: 297–303.
13. De Santos M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer ‘unfit’ for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol 2009; 27(33): 5634–5639.
14. Culine S, Fléchon A, Guillot A et al. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urethral unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). Eur Urol 2011; 60(6): 1251–1257.
15. Galsky MD, Iasonos A, Mironov S et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced...
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

K. N. Chi†*, T. Kheoh², C. J. Ryan³, A. Molina⁴, J. Bellmunt⁵, N. J. Vogelzang⁶, D. E. Rathkopf⁷, K. Fizazi⁸, P. W. Kantoff⁵, J. Li⁹, A. A. Azad⁴, B. J. Egi¹, D. Y. C. Heng¹⁰, A. M. Joshua¹¹, J. S. de Bono¹² & H. I. Scher¹³

1Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada; 2Janssen Research & Development, San Diego; 3Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco; 4Janssen Research & Development, Menlo Park; 5Department of Solid Tumor Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 6Comprehensive Cancer Centers of Nevada, Las Vegas; 7Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA; 8Groupe Uro-Genitologie, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; 9Johnson & Johnson Medical China, Shanghai, China; 10Tom Baker Cancer Center and University of Calgary, Calgary; 11Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Canada; 12Drug Development Unit, Division of Cancer Therapeutics/ Clinical Studies, The Institute for Cancer Research and Royal Marsden Hospital, Sutton, UK; 13Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA

Received 19 June 2015; revised 25 November 2015; accepted 27 November 2015

Background: Few prognostic models for overall survival (OS) are available for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with recently approved agents. We developed a prognostic index model using readily available clinical and laboratory factors from a phase III trial of abiraterone acetate (hereafter abiraterone) in combination with prednisone in post-docetaxel mCRPC.

Patients and methods: Baseline data were available from 762 patients treated with abiraterone–prednisone. Factors were assessed for association with OS through a univariate Cox model and used in a multivariate Cox model with a stepwise procedure to identify those of significance. Data were validated using an independent, external, population-based cohort.

Results: Six risk factors individually associated with poor prognosis were included in the final model: lactate dehydrogenase > upper limit of normal (ULN) [hazard ratio (HR) = 2.31], Eastern Cooperative Oncology Group performance status of 2 (HR = 2.19), presence of liver metastases (HR = 2.00), albumin ≤4 g/dl (HR = 1.54), alkaline phosphatase > ULN phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001; 19 (12): 3018–3024.

21. Albers P, Park SI, Niegisch G et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011; 22(2): 288–294.

22. Pond GR, Bellmunt J, Fougery R et al. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer 2013; 11(4): 495–500.

23. Sonpavde G, Bellmunt J, Rosenberg JE et al. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer 2014; 12(6): 395–398.

24. Krajewski KM, Fougery R, Bellmunt J et al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer 2012; 48(10): 1495–1502.